<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00352079</url>
  </required_header>
  <id_info>
    <org_study_id>BL11</org_study_id>
    <secondary_id>CAN-NCIC-BL11</secondary_id>
    <secondary_id>CDR0000486873</secondary_id>
    <nct_id>NCT00352079</nct_id>
  </id_info>
  <brief_title>BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer</brief_title>
  <official_title>A Phase III Study of IRESSA in Combination With Intravesical BCG Versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as BCG, may stimulate the immune system in different&#xD;
      ways and stop tumor cells from growing. Gefitinib may stop the growth of tumor cells by&#xD;
      blocking some of the enzymes needed for cell growth. Giving BCG together with gefitinib may&#xD;
      kill more tumor cells. It is not yet known whether BCG is more effective with or without&#xD;
      gefitinib in treating bladder cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying BCG and gefitinib to see how well they&#xD;
      work compared to BCG alone in treating patients with high-risk bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the impact of gefitinib and intravesical BCG vs intravesical BCG alone on time&#xD;
           to treatment failure in patients with high-risk, superficial transitional cell carcinoma&#xD;
           of the bladder.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the complete response rates in patients with carcinoma in situ receiving&#xD;
           gefitinib and intravesical BCG vs patients receiving intravesical BCG alone.&#xD;
&#xD;
        -  Compare the time to recurrence in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the time to progression in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Characterize and contrast the adverse event and safety profile of these regimens in&#xD;
           these patients.&#xD;
&#xD;
        -  Compare the effects of these regimens on quality of life in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, prospective, open-label, controlled, multicenter study.&#xD;
      Patients are stratified according to study center, status of tumor (primary vs recurrent),&#xD;
      carcinoma in situ (yes vs no), prior BCG therapy (yes vs no), and single dose of intravesical&#xD;
      mitomycin C at the time of the most recent transurethral resection (yes vs no). Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive induction therapy comprising intravesical BCG once weekly for 6&#xD;
           weeks. Patients then receive maintenance therapy comprising intravesical BCG once weekly&#xD;
           for 3 weeks.&#xD;
&#xD;
        -  Arm II: Patients receive induction therapy comprising intravesical BCG once weekly for 6&#xD;
           weeks and oral gefitinib once daily for 12 weeks. Patients then receive maintenance&#xD;
           therapy comprising intravesical BCG once weekly for 3 weeks and oral gefitinib once&#xD;
           daily for 12 weeks.&#xD;
&#xD;
      In both arms, treatment with maintenance therapy repeats at 3, 6, 12, 18, 24, 30, and 36&#xD;
      months for a total of 7 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, periodically during study therapy, and then at 3 and&#xD;
      6 months after completion of study therapy.&#xD;
&#xD;
      After study completion, patients are followed every 3 months for 2 years, every 6 months for&#xD;
      4 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 166 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    terminated due to poor accrual&#xD;
  </why_stopped>
  <start_date type="Actual">April 12, 2006</start_date>
  <completion_date type="Actual">January 6, 2012</completion_date>
  <primary_completion_date type="Actual">January 6, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate in patients with carcinoma in situ</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event and safety profile</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Intravesicle BCG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction:&#xD;
q weekly x 6 (cycle 1)&#xD;
Maintenance:&#xD;
q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months postrandomization (cycles 2 - 8)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iressa and Intravesicle BCG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravesical BCG:&#xD;
Induction:&#xD;
q weekly x 6 (cycle 1)&#xD;
Maintenance:&#xD;
q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)&#xD;
Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG vaccine</intervention_name>
    <description>Intravesical BCG:&#xD;
Induction:&#xD;
q weekly x 6 (cycle 1)&#xD;
Maintenance:&#xD;
q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)</description>
    <arm_group_label>Intravesicle BCG</arm_group_label>
    <arm_group_label>Iressa and Intravesicle BCG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)</description>
    <arm_group_label>Iressa and Intravesicle BCG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Each cycle and at 3 and 6 months after treatment discontinuation</description>
    <arm_group_label>Intravesicle BCG</arm_group_label>
    <arm_group_label>Iressa and Intravesicle BCG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed transitional cell carcinoma (TCC) of the bladder meeting ≥ 1&#xD;
             of the following criteria:&#xD;
&#xD;
               -  Noninvasive papillary carcinoma (Ta) with ≥ 1 of the following characteristics:&#xD;
&#xD;
                    -  Recurrence of bladder tumor(s) ≥ grade 2 within 6 months after transurethral&#xD;
                       resection (TUR)&#xD;
&#xD;
                    -  Three or more bladder tumors ≥ grade 2 at the time of TUR&#xD;
&#xD;
                    -  Bladder tumor(s) ≥ 5 cm in size and ≥ grade 2 at the time of TUR&#xD;
&#xD;
                    -  Any grade 3 bladder tumor(s)&#xD;
&#xD;
               -  Carcinoma in situ (Tis)&#xD;
&#xD;
               -  At least grade 2 tumor that invades the subepithelial connective tissue (T1)&#xD;
&#xD;
          -  Has undergone TUR of all visible bladder lesions within the past 21 to 60 days with&#xD;
             biopsy of the underlying bladder wall for all tumors and cold-cup biopsy of all&#xD;
             suspicious areas&#xD;
&#xD;
          -  No metastatic disease as confirmed by negative radiology within the past 16 weeks,&#xD;
             including the following:&#xD;
&#xD;
               -  Chest x-ray&#xD;
&#xD;
               -  Imaging of the upper urinary tract by 1 of the following methods:&#xD;
&#xD;
                    -  CT scan, MRI, or ultrasound of the abdomen and pelvis&#xD;
&#xD;
                    -  Intravenous pyelogram&#xD;
&#xD;
                    -  Retrograde pyelogram&#xD;
&#xD;
          -  No evidence of TCC of the upper urinary tract&#xD;
&#xD;
          -  No mixed histology of bladder cancer (i.e., TCC and squamous cell carcinoma of the&#xD;
             bladder or TCC and small cell carcinoma of the bladder) at the most recent TUR&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 5 years&#xD;
&#xD;
          -  Negative routine urine microscopy and negative urine culture within the past 14 days&#xD;
&#xD;
          -  Willing to complete quality of life questionnaires in English or French&#xD;
&#xD;
               -  Inability to complete questionnaires due to illiteracy in English or French, loss&#xD;
                  of sight, or other reason allowed&#xD;
&#xD;
          -  WBC ≥ 3,000/mm³&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             completion&#xD;
&#xD;
          -  No significant history of cardiac disease including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Uncontrolled high blood pressure&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Myocardial infarction within the past year&#xD;
&#xD;
               -  Cardiac ventricular arrhythmias requiring medication&#xD;
&#xD;
          -  No active urinary tract infection&#xD;
&#xD;
          -  No active infection, including tuberculosis&#xD;
&#xD;
          -  No serious underlying medical conditions that would impair the ability of the patient&#xD;
             to receive protocol treatment&#xD;
&#xD;
          -  No febrile illness or gross hematuria&#xD;
&#xD;
          -  No impaired immune response from any cause (congenital, therapy, or disease)&#xD;
&#xD;
          -  No clinically significant or untreated ophthalmologic condition (e.g., Sjögren's&#xD;
             syndrome)&#xD;
&#xD;
          -  No gastrointestinal conditions (e.g., Crohn's disease or ulcerative colitis)&#xD;
&#xD;
          -  No history of psychiatric or neurological disorder that would limit study compliance&#xD;
&#xD;
          -  No other malignancies except for adequately treated nonmelanoma skin cancer,&#xD;
             curatively treated in situ cancer of the cervix, or other solid tumors curatively&#xD;
             treated with no evidence of disease for ≥ 5 years&#xD;
&#xD;
          -  No contraindications to spinal or general anesthesia as required for a TUR&#xD;
&#xD;
          -  No known hypersensitivity to BCG or gefitinib&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to the study drugs&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 12 months since prior intravesical immunotherapy (including BCG +/-&#xD;
             interferon)&#xD;
&#xD;
          -  More than 6 months since prior intravesical chemotherapy (including mitomycin C,&#xD;
             thiotepa, doxorubicin hydrochloride)&#xD;
&#xD;
               -  Single dose of intravesical mitomycin C at the time of the most recent TUR&#xD;
                  (within the past 21 to 60 days) allowed if considered standard care&#xD;
&#xD;
          -  No other prior or concurrent immune modulator therapy&#xD;
&#xD;
          -  No prior pelvic radiation&#xD;
&#xD;
          -  No prior gefitinib&#xD;
&#xD;
          -  No other concurrent experimental anticancer drugs&#xD;
&#xD;
          -  No concurrent use of drugs that induce CYP3A4 enzymes that have been shown to&#xD;
             significantly reduce plasma concentrations of gefitinib (including phenytoin,&#xD;
             carbamazepine, barbiturates, rifampin, or Hypericum perforatum [St. John's wort])&#xD;
&#xD;
          -  No concurrent grapefruit juice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis Lacombe, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire de Quebec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Unit at Vancouver Coastal</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton and District Urology Association</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUQ-Pavillon Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 13, 2006</study_first_submitted>
  <study_first_submitted_qc>July 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2006</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>stage 0 bladder cancer</keyword>
  <keyword>stage I bladder cancer</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

